Stéphanie Rouanet - Concepedia

Author

Stéphanie Rouanet

Inserm ORCID

Also Known As

Keith G. Oldroyd, Rouanet, Stephanie, S R Rouanet, S Rouanet, S. Rouanet, Stephanie Rouanet, Stéphanie Rouanet

103

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Inserm Sorbonne Université Assistance Publique – Hôpitaux de Paris Roche (France)Université Paris Cité

About

Stéphanie Rouanet is an author at Inserm specializing in medicine, cardiology, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	490
2	Public Health	4	4	203
3	Biomedical Engineering	1	1	19
4	Biostatistics	1	1	12
5	Diabetes	1	1	43

Stéphanie Rouanet

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry) G Montalescot, Jean Dallongeville, Éric Van Belle, European Heart Journal	2006	331
B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six‐month, national, multicenter, open‐label study Jérémie Sellam, Houria Hendel‐Chavez, Stéphanie Rouanet, Arthritis & Rheumatism	2011	154
Long-Term Mortality and Early Valve Dysfunction According to Anticoagulation Use Pavel Overtchouk, Paul Guedeney, Stéphanie Rouanet, Journal of the American College of Cardiology ThrombosisCardiovascular DiseasePatient SafetyEarly Valve DysfunctionValve Disease	2018	114
Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis Jérémie Sellam, Stéphanie Rouanet, Houria Hendel-Chavez, Arthritis & Rheumatism	2011	96
Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab Adeline Ruyssen‐Witrand, Stéphanie Rouanet, Bernard Combe, Annals of the Rheumatic Diseases	2012	89
Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial Xavier Mariette, Stéphanie Rouanet, Jean Sibilia, Annals of the Rheumatic Diseases	2013	78
Topical Ketoprofen Patch (100 mg) for the Treatment of Ankle Sprain: A Randomized, Double-Blind, Placebo-Controlled Study Bernard Mazières, Stéphanie Rouanet, Joanne Velicy, The American Journal of Sports Medicine	2005	74
High Risk of Heart Failure Associated with Desmoglein-2 Mutations Compared to Plakophilin-2 Mutations in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia Alexis Hermida, Véronique Fressart, Françoise Hidden‐Lucet, European Journal of Heart Failure	2019	67
The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis Karine Briot, Stéphanie Rouanet, Thierry Schaeverbeke, Joint Bone Spine InflammationRheumatologyBone DiseaseRheumatoid DisorderAutoimmune Disease	2014	60
Use of Whole‐Blood Transcriptomic Profiling to Highlight Several Pathophysiologic Pathways Associated With Response to Rituximab in Patients With Rheumatoid Arthritis: Data From a Randomized, Controlled, Open‐Label Trial Jérémie Sellam, Sandrine Marion‐Thore, Florent Dumont, Arthritis & Rheumatology	2014	59

Page 1